Healthtech
Q3 202418.07.2024

Drug discovery (Q3 2024)

Picture of Kai Nicol-Schwarz

Kai Nicol-Schwarz

at Sifted

Developing drugs is a very long and expensive process. It can take between 10 and 15 years and cost more than $1bn to bring one to market. It’s also hit and miss — with the latter doing most of the heavy lifting. 90% of drugs that make it to human trials — the final stage before approval — fail.

But increasingly startups are looking to speed up the process using new tech like proprietary machine learning algorithms and generative AI. While some are looking to develop their own drug candidates, others are building tools to be used by pharma companies and other biotechs.

For startups, there are reasons to be cheerful. AI and ML present a “huge opportunity” for tech companies to solve problems in the drug discovery space, one investor tells Sifted. Another says the approaching “patent cliff” — which will see several revenue-driving drug patents expire — is an “unprecedented opportunity” for startups as pharma companies look to bolster drug pipelines. Others say they’ve noticed lead times to sell into pharma drop since pre-Covid times.

Positive moves — but it’s still early days. While there are some AI-developed drugs in clinical trials, none have yet made it to market. With or without startups — drug discovery is a long game. Investors say major AI-driven advances in the drug discovery process will likely come in the next decade, rather than the next few years. But, if VC confidence in the sector holds, there’s every chance startups could play an increasingly key role in the sector going forward.

20 startups to watch

  • CHARM Therapeutics logo

    Sifted score

    9.13
    -

    CHARM Therapeutics

    3D deep learning for undruggable diseases.

    • Strong investor(s)
    • Serial founder(s)

    • Year founded

      2021

    • HQ

      London, United Kingdom

    • Latest round

      Early VC
      €18.2m / Apr 2023

    • Total funding

      €75.1m

    View company profile
  • Aqemia logo

    Sifted score

    9.02
    -

    Aqemia

    • Strong investor(s)
    • Serial founder(s)
    • Hiring

    • Year founded

      2019

    • HQ

      Paris, France

    • Latest round

      Series A
      €30m / Jan 2024

    • Total funding

      €70.9m

    View company profile
  • Chemify logo

    Sifted score

    8.08
    -

    Chemify

    • Strong investor(s)
    • Serial founder(s)
    • Hiring

    • Year founded

      2022

    • HQ

      Glasgow, United-Kingdom

    • Latest round

      Series A
      €39.8m / Aug 2023

    • Total funding

      €39.8m

    View company profile
  • Abzu logo

    Sifted score

    7.98
    -

    Abzu

    Explainable AI for pharmaceutical research.

    • Strong investor(s)
    • Serial founder(s)

    • Year founded

      2018

    • HQ

      Copenhagen, Denmark

    • Latest round

      Grant
      €2.5m / Jun 2022

    • Total funding

      €10.4m

    View company profile
  • Kvantify logo

    Sifted score

    7.97
    -

    Kvantify

    • Strong investor(s)
    • Serial founder(s)

    • Year founded

      2022

    • HQ

      Copenhagen, Denmark

    • Latest round

      Grant
      €2m / Oct 2023

    • Total funding

      €9m

    View company profile

Related Briefings

Related articles

Europe’s VCs are increasingly taking on jobs at their startups
Venture capitalAnalysis

July 17, 2026

Europe’s VCs are increasingly taking on jobs at their startups

By Anne Sraders

Pro

From chatbots to ‘digital teammates’: The shift towards multiplayer AI
Artificial intelligenceSponsored by

July 17, 2026

From chatbots to ‘digital teammates’: The shift towards multiplayer AI

From chatbots to ‘digital teammates’: The shift towards multiplayer AI
Sponsored by Dust
Mollie doubles down on Europe with €350m expansion plan: ‘Superapp is a convoluted word’
Interview

July 17, 2026

Mollie doubles down on Europe with €350m expansion plan: ‘Superapp is a convoluted word’

Koen Koppen Mollie
By Damisola Sulaiman

Pro

The sectors with the most momentum heading into H2
Venture capitalSifted data

July 17, 2026

The sectors with the most momentum heading into H2

Sifted dug into the data to discover the hottest sectors across Europe in the first half of 2026

By Jonathan Sinclair

Pro

Exclusive: EQT’s €5bn Scaleup Fund in talks to lead Mistral round
Artificial intelligenceExclusive

July 16, 2026

Exclusive: EQT’s €5bn Scaleup Fund in talks to lead Mistral round

By Freya Pratty and Daphné Leprince-Ringuet

Pro

From pilot to production: How scaling companies are making AI work
Artificial intelligenceSifted Talks

July 16, 2026

From pilot to production: How scaling companies are making AI work

From pilot to production: How scaling companies are making AI work
Sponsored by Box
Munich robotics startup Microagi raises $55m, Germany’s largest ever seed round
RoboticsNews

July 16, 2026

Munich robotics startup Microagi raises $55m, Germany’s largest ever seed round

By Éanna Kelly
‘We want to make bookkeeping less painful’: How Visma and its AI portfolio are reshaping accounting
Artificial intelligenceSponsored by

July 16, 2026

‘We want to make bookkeeping less painful’: How Visma and its AI portfolio are reshaping accounting

‘We want to make bookkeeping less painful’: How Visma and its AI portfolio are reshaping accounting
Sponsored by Visma
European rounds are getting bigger, but fewer companies are closing them
Sifted data

July 16, 2026

European rounds are getting bigger, but fewer companies are closing them

A 20 Euro bill folded up into a shirt
By Federico Scolari

Pro

Europe’s most valuable board members, according to founders
Startup lifeList

July 16, 2026

Europe’s most valuable board members, according to founders

Europe’s most valuable board members, according to founders
By Freya Pratty, Mimi Billing and Maya Dharampal-Hornby

Pro

Europe’s leading tech hubs by deal activity in H1 2026
Sifted viewSifted data

July 16, 2026

Europe’s leading tech hubs by deal activity in H1 2026

London
By Ruggero Di Spigna

Pro

EQT-backed Syntetica raises $30m backed by Lululemon
Climate techNews

July 16, 2026

EQT-backed Syntetica raises $30m backed by Lululemon

Syntetica is currently working with brands including Victoria’s Secret and Etam

By Freya Pratty
From Tesla to building humanoids: Uma cofounder on why Europe is ‘the best market in the world’
RoboticsInterview

July 16, 2026

From Tesla to building humanoids: Uma cofounder on why Europe is ‘the best market in the world’

Uma cofounder Rémi Cadène
By Daphné Leprince-Ringuet

Pro

Robotics startup Monumental raises $32m backed by Khosla Ventures
RoboticsNews

July 15, 2026

Robotics startup Monumental raises $32m backed by Khosla Ventures

By Ellie Apostolidi
Yann LeCun launched a new VC fund — then quit. What happened?
Venture capitalPodcast

July 15, 2026

Yann LeCun launched a new VC fund — then quit. What happened?

By Maya Dharampal-Hornby
Exclusive: Aramco in talks to back Humanoid at unicorn valuation
RoboticsExclusive

July 15, 2026

Exclusive: Aramco in talks to back Humanoid at unicorn valuation

By Freya Pratty and Tom Nugent

Pro

Europe’s ‘real’ founder factories: Klarna and Improbable
Startup lifeAnalysis

July 15, 2026

Europe’s ‘real’ founder factories: Klarna and Improbable

Europe’s ‘real’ founder factories: Klarna and Improbable
By Éanna Kelly
It’s time to start paying all your staff like your sales team
Startup lifeOpinion

July 15, 2026

It’s time to start paying all your staff like your sales team

It’s time to start paying all your staff like your sales team
By Julio Martinez
The incubator launching Scotland’s next generation of tech: ‘We need to pull the bigger players into the Scottish market’
Venture capitalSponsored by

July 15, 2026

The incubator launching Scotland’s next generation of tech: ‘We need to pull the bigger players into the Scottish market’

The incubator launching Scotland’s next generation of tech: ‘We need to pull the bigger players into the Scottish market’
Sponsored by Techscaler
Can Neko's unflattering avatars actually change behaviour?
HealthtechOpinion

July 15, 2026

Can Neko's unflattering avatars actually change behaviour?

Neko Health's body scanning avatar
By Mimi Billing
Neko raises $700m Series C: ‘We now have 100k members and are profitable at clinic level’
HealthtechInterview

July 15, 2026

Neko raises $700m Series C: ‘We now have 100k members and are profitable at clinic level’

The body scanning startup Neko Health's CEO Hjalmar Nilsonne.
By Mimi Billing

Pro

European biotech mapped: 90 startups reshaping medicine
BiotechMarket map

July 15, 2026

European biotech mapped: 90 startups reshaping medicine

From drug discovery to gene editing, these startups are transforming the future of medicine

By Oshin Narang

Pro

The ex-Palantir and Dropbox duo helping the likes of ElevenLabs, Notion and Wiz ship AI-generated code faster
Artificial intelligenceNews

July 15, 2026

The ex-Palantir and Dropbox duo helping the likes of ElevenLabs, Notion and Wiz ship AI-generated code faster

By Tom Nugent
Why late-stage secondary offerings are transforming private market access
HealthtechPaid for and produced by

July 14, 2026

Why late-stage secondary offerings are transforming private market access

Why late-stage secondary offerings are transforming private market access
Paid for and produced by Republic